New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma

Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory...

Full description

Saved in:
Bibliographic Details
Published inFarmakoèkonomika (Moskva. Online) Vol. 16; no. 2; pp. 291 - 302
Main Authors Sorokina, M. А., Rakhteenko, A. V., Grishina, T. R.
Format Journal Article
LanguageEnglish
Russian
Published IRBIS LLC 01.07.2023
Subjects
azacitidine
biomarkers
bortezomib
duvelisib
peripheral t cell lymphoma
personalized medicine
romidepsin
Online AccessGet full text

Cover

More Information
Summary:Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory and recurrent PTCL who do not respond to such therapy or demonstrate adverse events, which makes it important to personalize therapy and search for predictive markers, followed by thorough analytical and clinical validation. The literature highlights the importance of using biomarkers obtained from whole exome sequencing and tumor transcriptome sequencing. The review discusses the T cell ontogenesis, as well as the possibilities of personalization of anticancer drugs such as azacitidine, duvelisib, romidepsin, and bortezomib for the treatment of refractory or recurrent PTCL.
ISSN:2070-4909
2070-4933
DOI:10.17749/2070-4909/farmakoekonomika.2023.170